Market Snapshot – Viatris Inc. (VTRS)
At 11:01 AM Central Europe on Thursday 22 October 2026, the stock of Viatris Inc. (NASDAQ: VTRS) closed 1.07 % lower than the previous trading session. The current trading price sits at approximately USD 18.45 per share, a figure that has been readily available on the most widely used exchanges.
With a free‑float supply of 1.1 billion shares, the company’s market capitalisation stands at roughly USD 21.4 billion. Over the past 24 hours, a total of USD 188 million worth of Viatris shares exchanged hands, a volume that represents a modest yet significant portion of the company’s outstanding equity.
In comparison to the month‑end figure, Viatris has experienced a 7.39 % increase, reflecting a steady upward trajectory in investor sentiment. The 200‑day simple moving average (SMA) is currently at USD 15.69, indicating that the share price has maintained a position above this long‑term mean for a considerable period.
The most recent high within the last 52 weeks was USD 18.75, reached on 19 October 2026, while the trough stood at USD 9.92 on 7 November 2025. These historical extremes provide context for the present valuation and suggest a moderate volatility profile.
Comparative Performance of Peer Stocks
To gauge Viatris’s relative performance, it is instructive to review the movements of several comparable companies in the same 24‑hour window:
| Company | Ticker | % Move | Current Price (USD) | Market Capitalisation (USD bn) | P/E Ratio |
|---|---|---|---|---|---|
| Verisk Analytics | VRSK | +0.77 % | 192.34 | 24.8 | 29.3 |
| Viatris Inc. | VTRS | ‑1.07 % | 18.45 | 21.4 | — |
| Affymetrix | AFRM | ‑0.46 % | 73.51 | 24.9 | 13.38 |
| Copart | CPRT | ‑0.86 % | 27.59 | 25.6 | 17.8 |
| Fiserv | FISV | ‑0.08 % | 48.21 | 25.6 | 9.23 |
| Roivant Sciences | ROIV | +5.38 % | 36.80 | 25.2 | — |
While most peers exhibited modest declines, Roivant Sciences’ 5.38 % gain stands out, signalling potential sector‑specific catalysts that are not reflected in Viatris’s current valuation.
Notable Corporate Developments
Verisk Analytics filed a Form 144 notice with the SEC on 20 October 2026, revealing a substantial sale of its common stock by an officer. The transaction was executed through a broker‑assisted, cashless mechanism on the NASDAQ, involving shares acquired via employee stock options and restricted‑stock‑unit vesting. No material business changes were reported beyond the sale.
Fiserv has partnered with TransUnion to launch a transaction‑matching service that links in‑store purchase activity with privacy‑respecting customer identities. Leveraging Fiserv’s Unknown Shopper technology, the solution helps merchants distinguish repeat customers from new ones even when different payment methods are used. This collaboration aims to reduce duplicate records and payment‑method blind spots, offering merchants a more comprehensive view of consumer behavior while preserving privacy.
Company Overview
Viatris Inc. is a global pharmaceutical entity that develops and markets medicines across a wide spectrum of therapeutic areas, encompassing both non‑communicable and infectious diseases. With a presence in numerous international markets, Viatris serves a diverse patient population and maintains a robust product pipeline. The company is listed on the NASDAQ stock exchange and operates its online platform at www.viatris.com/en .
This article synthesises publicly available market data and recent corporate filings to provide an up‑to‑date overview of Viatris Inc.’s market performance and its relative standing among peer companies.
